Nitrofurantoin
- Generic Name
- Nitrofurantoin
- Brand Names
- Furadantin, Macrobid, Macrodantin
- Drug Type
- Small Molecule
- Chemical Formula
- C8H6N4O5
- CAS Number
- 67-20-9
- Unique Ingredient Identifier
- 927AH8112L
- Background
Nitrofurantoin is a nitrofuran antibiotic used to treat uncomplicated urinary tract infections. Nitrofurantoin is converted by bacterial nitroreductases to electrophilic intermediates which inhibit the citric acid cycle as well as synthesis of DNA, RNA, and protein. This drug is more resistant to the development of bacterial resistance because it acts on many targets at once. Nitrofurantoin is a second line treatment to trimethoprim/sulfamethoxazole.
Nitrofurantoin was granted FDA approval on 6 February 1953.
- Indication
Nitrofurantoin is indicated to treat acute uncomplicated urinary tract infections.
- Associated Conditions
- Acute Cystitis, Urinary Tract Infection
FDA Approves Blujepa, First New Class of Oral Antibiotic for UTIs in Nearly 30 Years
• GSK's Blujepa (gepotidacin) has received FDA approval for treating uncomplicated urinary tract infections, marking the first new class of oral antibiotics for UTIs in nearly three decades.
• The novel triazaacenaphthylene antibiotic demonstrated non-inferiority or superiority to nitrofurantoin in clinical trials, offering a new treatment option amid rising antibiotic resistance concerns.
• Blujepa works through a unique dual-enzyme inhibition mechanism that may reduce the potential for resistance development, with commercial availability expected in the second half of 2025.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath